我們已在上線！進一步了解

AbCellera Biologics

ABCL

市值 US$38.2億

11.80 USD

-0.88

6.94%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

11.80

0.00

0%

1天

-6.94%

5天

-7.16%

1個月

1.11%

3個月

91.56%

6個月

208.09%

今年迄今

244.02%

1年

102.05%

5年

-22.77%

10年

-79.97%

關於： AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

員工： 562

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 34.8%

中性 60.9%

負面 4.3%

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

Zacks Investment Research

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.

What'sGoing On With AbCellera Biologics Stock On Tuesday?

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at alleviating menopausal hot flashes.

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

查看新聞排名

價格圖表採用Lightweight Charts™實作